Imeglimin Halts Liver Damage by Improving Mitochondrial Dysfunction in a Nondiabetic Male Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis

Imeglimin Halts Liver Damage by Improving Mitochondrial Dysfunction in a Nondiabetic Male Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis

Imeglimin promotes glucose-stimulated insulin secretion in the pancreas in a glucose-dependent manner and inhibits gluconeogenesis in the liver. Meanwhile, imeglimin can improve mitochondrial function in hepatocytes. We used a nondiabetic metabolic dysfunction-associated steatohepatitis (MASH) model...

Full description

Saved in:
Bibliographic Details
Main Authors: Kosuke Kaji, Soichi Takeda, Satoshi Iwai, Norihisa Nishimura, Shinya Sato, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Antioxidants
Subjects:
imeglimin
hepatocyte
metabolic dysfunction-associated steatohepatitis
fatty acid oxidation
reactive oxygen species
mitochondrial biogenesis
Online Access:https://www.mdpi.com/2076-3921/13/11/1415
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items